Antioxidant Therapy Guidelines for Male Infertility

Guideline Position

Clinical Pitfalls

Lifestyle Interventions Prioritized Over Antioxidants

Decision‑Making Algorithm (Evidence‑Based Steps)

Safety Considerations

Penggunaan Antioksidan pada Kelainan Sperma

Bukti Ilmiah tentang Antioksidan dan Kelainan Sperma

• Stres oksidatif memang berperan penting dalam disfungsi sperma dan infertilitas pria, namun bukti klinis untuk penggunaan antioksidan masih terbatas dan berkualitas rendah 2, 3
• Tinjauan Cochrane yang menganalisis 48 studi menemukan bahwa hanya 7 dari 48 uji klinis yang melaporkan tingkat kehamilan klinis, dan hanya 4 yang melaporkan kelahiran hidup 4, 2
• Bukti berkualitas rendah dari hanya 4 RCT kecil menunjukkan bahwa suplementasi antioksidan pada pria infertil mungkin meningkatkan tingkat kelahiran hidup, tetapi data tentang efek samping masih kurang 4, 5

Rekomendasi Klinis

• Pedoman dari Human Reproduction Update (2017) merekomendasikan bahwa data yang tersedia tidak cukup untuk merekomendasikan penggunaan terapi antioksidan tambahan untuk pengobatan pria dengan parameter semen abnormal dan/atau infertilitas pria 4, 5, 2
• European Association of Urology (2025) menyatakan bahwa bukti untuk peran terapi antioksidan dalam infertilitas pria masih bertentangan 6
• American Urological Association/American Society for Reproductive Medicine (2021) menyarankan agar klinisi memberi tahu pasien bahwa manfaat suplemen memiliki kegunaan klinis yang dipertanyakan dalam mengobati infertilitas pria 7

Efek Antioksidan pada Parameter Sperma

• Kualitas metodologi sebagian besar studi tentang antioksidan dan terapi herbal untuk mengobati infertilitas pria masih buruk 4, 5, 2
• Heterogenitas studi yang dipilih membuat meta-analisis menjadi tantangan tersendiri 4, 5
• Teknik untuk mengukur stres oksidatif, kapasitas antioksidan, dan/atau kerusakan DNA tidak distandarisasi di antara semua uji klinis 4, 5

Guideline Recommendations and Evidence Quality for Coenzyme Q10 Use in Male Infertility

1. Guideline Stance and Evidence Strength

• The European Association of Urology (2025) states that the evidence for antioxidant therapy, including CoQ10, is “conflicting” and of low quality, and it recommends against routine use of such supplements in male infertility management. 8
• A Cochrane review of 48 randomized studies identified only 4 trials that reported live‑birth outcomes, concluding that the evidence is insufficient to draw clear conclusions about the clinical benefit of CoQ10 for fertility. 9

2. Limitations of Current Research

• Most CoQ10 trials assess surrogate semen parameters (e.g., concentration, motility) rather than live‑birth rates, limiting the relevance of findings to actual fertility outcomes. 9
• The methodological quality of existing studies is poor, with significant heterogeneity across trials, undermining confidence in pooled results. 8
• No standardized, validated assays exist for measuring oxidative stress (reactive oxygen species) in seminal fluid, restricting the ability to monitor treatment effects. 8

3. Baseline Evaluation Prior to Supplementation

• Perform at least two semen analyses following WHO criteria before initiating any antioxidant therapy. 8
• Obtain a comprehensive medical and reproductive history that includes smoking status, body‑mass‑index, heat‑exposure habits, medication use, and presence of varicocele. [9][8]
• Conduct a physical examination to identify any correctable urological or systemic causes of infertility. 8
• Consider, but do not routinely recommend, sperm DNA‑fragmentation testing; it may be used selectively when available. 8

4. Lifestyle Modifications with Stronger Evidence

• Smoking cessation is supported by the strongest evidence for improving male fertility and should be prioritized before or alongside any supplement trial. 9
• Avoidance of heat exposure (e.g., hot tubs, saunas, tight underwear) is recommended based on moderate evidence to enhance semen quality. 9

5. Clinical Decision Considerations for CoQ10

• In men whose female partners are ≥ 35 years old or when the couple has been attempting conception for > 12 months, referral to reproductive endocrinology should occur simultaneously with any CoQ10 trial, to avoid delaying definitive treatment. 8

6. Measurement and Outcome Caveats

• Routine measurement of reactive oxygen species in semen is not advised because of the lack of standardized testing methods. 8
• Improvements in semen parameters (e.g., concentration, motility) do not necessarily translate into higher live‑birth rates; live birth remains the only definitive fertility outcome. 9

Evidence Gaps and Safety of Antioxidant Supplements in Male Infertility

Outcome Reporting in Antioxidant Trials

• In a systematic review of 48 randomized trials evaluating antioxidant therapy for male infertility, only 7 trials reported clinical pregnancy rates and merely 4 trials reported live‑birth outcomes, the most clinically relevant endpoint, highlighting substantial under‑reporting of key fertility outcomes. This limitation reduces confidence in the overall efficacy conclusions. 10

Safety Profile of High‑Dose Vitamin C

• Clinical trials of vitamin C supplementation in men with infertility have not reported adverse events at doses up to 2000 mg per day, indicating a favorable safety profile for this antioxidant at therapeutic doses. 10